Rp-8-Br-cAMPS

Rp-8-Br-cAMPS is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS also inhibits insulin secretion[1][2][3].

Product Specifications

CAS Number

[129735-00-8]

UNSPSC

12352005

Target

PKA

Type

Reference compound

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rp-8-br-camps.html

Smiles

NC1=NC=NC2=C1N=C(Br)N2[C@H]3[C@H](O)[C@H](O4)[C@@H](CO[P@]4(S)=O)O3

Molecular Formula

C10H11BrN5O5PS

Molecular Weight

424.17

References & Citations

[1]Nayjib B, et al. In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice[J]. The Open Immunology Journal, 2008, 1 (1) .|[2]Raskovalova T, et al. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I) . Immunol Res. 2006;36 (1-3) :91-9.|[3]Yang S, et al. Enhanced cAMP protein kinase A signaling determines improved insulin secretion in a clonal insulin-producing beta-cell line (INS-1 832/13) . Mol Endocrinol. 2004 Sep;18 (9) :2312-20.